Polynovo

Polynovo EBITDA per Employee

The EBITDA per Employee of Polynovo (PNV.AX) as of Oct 28, 2026 is 173,107.69 AUD. In the previous year, EBITDA per Employee was 160,800.00 AUD — a change of 7.65% (higher).

EBITDA per Employee

173,107.69AUD

YoY

7.65%

Last updated:

EBITDA per Employee of Polynovo is 2026 173,107.69 AUD. EBITDA per Employee of Polynovo was 2025 160,800.00 AUD. It decreases by 7.65% higher compared to the previous year.

The Polynovo EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-90,036.92 AUD
Jan 1, 2020
-50,812.31 AUD
Jan 1, 2021
-92,866.15 AUD
Jan 1, 2022
20,492.31 AUD
Jan 1, 2023
-63,815.38 AUD
Jan 1, 2024
51,661.54 AUD
Jan 1, 2025
160,800.00 AUD
Jan 1, 2026
173,107.69 AUD
The Polynovo EBITDA per Employee history
YEAREBITDA per EmployeeYoY
173,107.69AUD+7.65%
160,800.00AUD+211.26%
51,661.54AUD-180.95%
-63,815.38AUD-411.41%
20,492.31AUD-122.07%
-92,866.15AUD+82.76%
-50,812.31AUD-43.57%
-90,036.92AUD-15.27%
-106,263.08AUD+41.02%
-75,353.85AUD+17.93%
-63,896.92AUD+10.35%
-57,904.62AUD-3.37%
-59,923.08AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polynovo Stock analysis

What does Polynovo do? Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery. Polynovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polynovo stock

EBITDA per Employee of Polynovo is 173,107.69 AUD in 2026.

EBITDA per Employee of Polynovo changed from 160,800.00 AUD to 173,107.69 AUD, representing a 7.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Polynovo since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Polynovo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Polynovo

All Key Metrics — Polynovo